Neuroendocrine Tumor Treatment Market, By Drug Class (Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy, Others), By Indication (Gastrointestinal NET, Lung NET, Pancreatic NET, Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Oct 2023

Code : CMI129

Pages :180

Formats :

Excel and PDF

Industry : Pharmaceutical

Regional Analysis

Global Neuroendocrine Tumor Treatment Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global neuroendocrine tumor treatment market over the forecast period due to key market players being focused on adopting strategies such as acquisition and merger to enhance their market share. For instance, on February 6, 2023, Isoray, Inc., a medical technology company pioneering in advanced treatment applications and devices to deliver targeted internal radiation treatments for cancers, announced the completion of the merger with Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company that is developing precision oncology therapeutics and complementary diagnostic imaging agents. Both companies will focus on the advancement of cancer treatments by using radiation, radiopharmaceuticals, and imaging technologies so that precision, targeted medical doses are delivered directly to cancer patient tumor sites. This merger will further help the company expand its product portfolio.

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa